Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

arges of $5.9 million in 2009 and $4.1 million in 2008; (4) Kuvan approval milestones received of $31.5 million earned in 2008; (5) the gross margin of the initial Aldurazyme product transfer to Genzyme of $2.3 million associated with the restructuring of BioMarin/Genzyme LLC in the first quarter of 2008; (6) gain on the sale of equity investments of $1.6 million in 2009 and (7) income tax effect of $0.3 million and $2.2 million in 2009 and 2008, respectively. The reconciliation of these measures to the estimated GAAP net income is detailed in the table provided at the end of the press release.

BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan and Aldurazyme and development of its pipeline. By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future. Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes.

Diluted Earnings Per Share Calculation

The calculation of GAAP diluted earnings per share for all of the 2009 periods presented and non-GAAP diluted earnings per share for the third quarter and first nine months of 2008 reflect the theoretical exclusion of the interest expense from net earnings that would no longer be incurred if the Company's convertible notes were converted into shares as their impact is considered anti-dilutive. Non-GAAP diluted earnings per share for the third quarter and first nine months of 2009 include 16.0 million shares related to the Company's convertible notes due in April 2017
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Pomerantz LLP is investigating claims ... or the "Company") (NASDAQ: VTAE ).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On February 27, 2015, the Company ...
(Date:2/27/2015)... -- Acsis Inc., the market leader for supply chain visibility, ... John DiPalo , Acsis, Chief Strategy Officer, has been ... 2015 Provider Pro to Know. The award recognizes ... prepare their companies, and customers, supply chains for the ... of Provider Pros to Know is featured in ...
(Date:2/27/2015)... , Israele, February 27, 2015 ... nel suo sviluppo dell,innovativo sistema di monitoraggio dell,infarto ... primo trial sull,uomo-     ... nello sviluppo di nuovo sistema per il monitoraggio ... (CHF), ha annunciato oggi di aver concluso una ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
(Date:3/1/2015)... 01, 2015 Indiana Fiber Network, ... Provider, announces NewWays Networking, LLC (NewWays) selected IFN ... with IFN, NewWays is well positioned to scale ... for Internet bandwidth in rural parts of Indiana,” ... to Cory Childs IFN Enterprise Sales Manager, IFN ...
(Date:3/1/2015)... CrossFit Attollo is a CrossFit gym located in Vancouver ... to new members. Now through the end of March ... will receive their fourth month half off. , ... The three month contract is only $264, dropping the price ... comes in at only $55. The special saves new members ...
(Date:2/28/2015)... 28, 2015 In a recent episode ... of Game Change Athlete Development Services and ... the benefits of athlete development and player engagement during ... unique challenges that athletes face and how off-field activities ... , Fletcher became involved in athlete development issues while ...
(Date:2/28/2015)... The Classic Denture Center , located ... Throughout all of March patients can receive $25 ... service can help overall mouth health and give ... notice certain symptoms that suggest the denture teeth are ... , 1.    Pain, clicking, and popping in the joints, 2.    Pain ...
(Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, a ... to announce the development of Q-Suite 5.9. Building off ... Q-Suite, this new version will include enhancements to existing ... to the leading edge call center software. General availability ... features to enhance security and protection. Administrators will be ...
Breaking Medicine News(10 mins):Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2
... has praised South Africa's malaria control programme,// saying the country's ... ,Wolfowitz visited the village of Mamitwa in ... malaria incidence ¯ last week (15 March). ... here is that this area has achieved one of the ...
... York University College of Dentistry research team has found ... to caries (tooth decay) and periodontal (gum) disease.// ... an Associate Professor of Epidemiology & Health Promotion and ... the largest-ever study on the oral health of immigrants ...
... fluids hold promise as a potential alternative to blood as ... cancers can be detected through the analysis of oral fluids. ... to detect meaningful amounts of disease markers in oral fluids, ... as in blood. Proteomics is a relatively new method of ...
... enamel is the hardest tissue produced by the body. It ... of cells that is lost by the time the tooth ... its lifetime vulnerable to wear, damage, and decay. // ... prospect of artificially growing enamel, or even whole teeth, using ...
... engineering has emerged as a promising alternative for ... tissues, circumventing the complications associated with traditional transplants.// ... regenerate damaged tissue by using engineered tissue substitutes ... integrate into the host tissue. ...
... tests and biopsy, saliva can be used to detect ... ~4 million American, 90% being women. pSS patients are ... develop lymphoma, a fatal lymphocytic cancer. ,Scientists at ... of salivary biomarkers that can distinguish pSS patients from ...
Cached Medicine News:Health News:World Bank Head Praises DDT Use Against Malaria 2Health News:Study Links Tooth Decay and Gum Infections to Ethnicity and Country of Origin 2Health News:Scientists Re-grow Dental Enamel from Cultured Cells 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: